Followers | 834 |
Posts | 120246 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Monday, May 14, 2007 1:59:50 PM
http://biz.yahoo.com/prnews/070514/ukm007.html?.v=101
>>
Monday May 14, 8:01 am ET
MR Guided Focused Ultrasound Offers Non-Invasive Alternative to Hysterectomy and Myomectomy
HAIFA, Israel, May 14 /PRNewswire/ -- InSightec Ltd. wants women suffering from uterine fibroids to know all their treatment options.
"Many women suffer from uterine fibroid symptoms for years because they fear or want to avoid hysterectomies that could not only have a permanent impact on their health, but require them to take weeks off from their jobs and families for recovery," said Phyllis J. Gee, MD, FACOG, and Director of North Texas Uterine Fibroid Institute. "Women have other options including focused ultrasound treatment with the ExAblate® system which is completely non-invasive and allows the patient to return home the same day and get back to her normal activities. We want women with uterine fibroids to know their options - and realize that invasive surgery isn't the only answer for symptom relief."
In honor of Mother's Day and Women's Health Week (May 13-19, 2007), InSightec and the U.S. sites that offer the ExAblate procedure are encouraging women suffering from the bleeding, anemia and abdominal pain associated with uterine fibroids to come in for a consultation to determine if they are eligible for the procedure.
"Uterine fibroid patients don't need to continue to suffer because they fear invasive treatments," said Dr. Kobi Vortman, President and CEO of InSightec. "We hope women throughout the U.S. use the National Women's Health Week to take time for themselves, visit their doctors and to learn about all their options when it comes to leading the healthiest lives possible."
Approximately 600,000 American women undergo hysterectomies each year and fibroids are the leading cause. When the U.S. Food and Drug Administration (FDA) approved the ExAblate system in 2004, it became - and remains today - the only non-invasive treatment for women suffering symptoms of these non-cancerous tumors in the uterus. To perform focused ultrasound, a physician uses Magnetic Resonance Imaging (MRI) to visualize tissue in the body, plan and monitor the treatment and then aims high-intensity focused ultrasound energy at the fibroid to destroy it. This process alleviates the painful symptoms of uterine fibroids while allowing a woman to retain her uterus.
To date 3,000 women have undergone the treatment worldwide.
For more information patients can call 1-866-ExAblate (1-866-392-2528). A list of all the sites offering the non-invasive procedure is available at www.uterine-fibroids.org.
About National Women's Health Week
National Women's Health Week is a nationwide initiative led by the U.S. Department of Health and Human Services' Office on Women's Health that calls attention to the importance of women's health. During the week, families, health organizations, businesses, communities, the government and individuals come together to raise awareness about women's health issues and educate women about simple steps they can take for a longer, healthier and happier life. The theme for National Women's Health Week 2007 is "It's Your Time: Pamper Your Mind, Body and Spirit."
National Women's Health Week kicks off on Mother's Day, May 13, and will be celebrated until May 19, 2007. National Women's Check-up Day - a day where women across the country are urged to visit their doctor - will be held on May 14, 2007. For more information about National Women's Health Week, please visit www.womenshealth.gov/whw.
About ExAblate® 2000
The ExAblate 2000 is the first system to use the breakthrough MRgFUS technology that combines MRI - to visualize tissues in the body, plan the treatment and monitor in real time treatment outcome - and high intensity focused ultrasound to thermally ablate uterine fibroid tissue. MR thermal feedback, provided uniquely by the system, allows the physician to control and adjust the treatment in real time to ensure that the targeted tumor is fully treated and surrounding tissue is spared. ExAblate received FDA approval for the treatment of symptomatic uterine fibroids in October 2004. ExAblate has been recognized for its innovation and potential to serve mankind and has been awarded the 2004 European Union's Information Society Technologies grand prize, The Wall Street Journal's 2004 Technology Innovation Awards, Advanced Imaging's 2005 Solutions of the Year, and most recently, the Red Herring 100 Europe 2007 Award.
Uterine fibroids are benign growths in the uterus that up to 30% of women of childbearing age. Symptomatic women suffer from extensive and prolonged menstrual bleeding, anemia, pain, pressure and often infertility. Existing treatment options include hysterectomy, myomectomy and uterine artery embolization and are invasive, involving hospitalization and several weeks of recovery time. ExAblate is an outpatient procedure and patients return home the same day and to work within one to two days.
About InSightec
InSightec Ltd. is a privately held company owned by Elbit Medical Imaging (EMI), General Electric, MediTech Advisors, LLC and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 135 employees and has invested more than $100 million in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas. For more information, please go to: http://www.insightec.com/
<<
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent RPRX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 01:02:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:20:53 AM
- Royalty Pharma Reports Second Quarter 2024 Results • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:04:01 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/29/2024 08:30:11 PM
- Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital • GlobeNewswire Inc. • 07/24/2024 12:30:00 PM
- Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 • GlobeNewswire Inc. • 07/19/2024 12:15:00 PM
- Royalty Pharma Declares Third Quarter 2024 Dividend • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:58:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:06:32 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/04/2024 09:12:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:57:02 PM
- Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 08:15:00 PM
- Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes • GlobeNewswire Inc. • 06/03/2024 09:15:27 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 06/03/2024 08:59:57 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/03/2024 01:13:40 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 06/03/2024 12:39:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 09:25:01 PM
- Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million • GlobeNewswire Inc. • 05/28/2024 11:10:00 AM
- Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline • GlobeNewswire Inc. • 05/22/2024 08:10:00 PM
- Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline • GlobeNewswire Inc. • 05/22/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:42:57 PM
- Royalty Pharma to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/13/2024 12:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 01:01:55 PM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM